Venom-Derived Cyclic Peptide Could Replace Antibody Therapy for Multiple Sclerosis with Fewer Risks
A small cyclic peptide derived from viper venom reduced MS-like disease in mice as effectively as current antibody treatments, with no immune reactions or toxic side effects.
Quick Facts
What This Study Found
Visabron c(4-4), a backbone cyclic octapeptide derived from viper venom disintegrin, effectively reduced EAE disease severity in mice while showing no immunogenicity or off-target toxicity.
Key Numbers
8-amino-acid cyclic peptide; dual alpha4beta1/alpha9beta1 antagonist; no immunogenicity; no off-target effects
How They Did This
Peptide design and synthesis from a minilibrary with conformational diversity. Functional adhesion cellular assays for potency/selectivity. Serum stability and pharmacokinetics testing. In vivo efficacy in EAE mouse model (IP injection). Safety assessed via blood analysis, tissue pathology, immunogenicity, and off-target effects.
Why This Research Matters
Natalizumab works well for MS but carries the risk of a serious brain infection (PML) with long-term use. A small peptide that does the same job without triggering immune reactions could be a safer alternative.
The Bigger Picture
Replacing monoclonal antibodies with small peptide mimetics is a major trend in pharmaceutical development. Visabron demonstrates that venom-derived peptides — shaped by evolution to interact precisely with integrins — can be re-engineered as safe, non-immunogenic drugs. Success in MS could open the door for similar approaches in Crohn's disease, ulcerative colitis, and other autoimmune conditions where α4 integrins play a role.
What This Study Doesn't Tell Us
Animal study only (mice with EAE, not humans with MS). EAE does not perfectly mirror human MS. Specific dosing and duration details limited. No head-to-head comparison with natalizumab in the same model. Long-term safety in animals not reported.
Questions This Raises
- ?Would visabron show efficacy in human MS clinical trials, given the limitations of the EAE mouse model?
- ?Could oral formulation of this cyclic peptide be achieved, or is injection required?
- ?How does visabron's integrin-blocking potency compare head-to-head with natalizumab in the same experimental system?
Trust & Context
- Key Stat:
- 8-amino-acid peptide venom-derived cyclic peptide matched antibody therapy's mechanism for MS with no immunogenicity and no off-target effects in mice
- Evidence Grade:
- Preclinical study with comprehensive characterization: in vitro selectivity assays, pharmacokinetics, in vivo efficacy in EAE mouse model, and extensive safety testing. Published in JACS Au (ACS journal). However, it remains animal data without human validation, and EAE doesn't perfectly model human MS.
- Study Age:
- Published in 2021 in JACS Au. The backbone cyclic peptide approach and venom-derived design represent active areas of peptide drug development.
- Original Title:
- Synthesis and Pharmacological Characterization of Visabron, a Backbone Cyclic Peptide Dual Antagonist of α4β1 (VLA-4)/α9β1 Integrin for Therapy of Multiple Sclerosis.
- Published In:
- JACS Au, 1(12), 2361-2376 (2021)
- Authors:
- Gilon, Chaim(4), Klazas, Michal, Lahiani, Adi, Schumacher-Klinger, Adi, Merzbach, Shira, Naoum, Johnny N, Ovadia, Haim, Rubin, Limor, Cornell-Kennon, Susan, Schaefer, Erik M, Katzhendler, Jehoshua, Marcinkiewicz, Cezary, Hoffman, Amnon, Lazarovici, Philip
- Database ID:
- RPEP-05406
Evidence Hierarchy
Frequently Asked Questions
Why is a small peptide potentially safer than the antibody natalizumab?
Natalizumab is a large antibody protein that strongly suppresses immune surveillance in the brain, which can allow a dormant virus (JC virus) to cause the deadly brain infection PML. Visabron is a tiny 8-amino-acid cyclic peptide that blocks the same integrin targets but doesn't trigger immune reactions (no immunogenicity) and may allow more nuanced immune modulation without the extreme suppression that enables PML.
How was viper venom used to design this drug?
Viper venoms contain disintegrins — proteins that block integrins to prevent blood clotting in prey. The researchers used a specific integrin-binding sequence (TMLD) from a viper disintegrin called visabres as the starting point, then engineered it into a small, stable cyclic peptide that retains the targeting ability while being safe and non-toxic.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05406APA
Gilon, Chaim; Klazas, Michal; Lahiani, Adi; Schumacher-Klinger, Adi; Merzbach, Shira; Naoum, Johnny N; Ovadia, Haim; Rubin, Limor; Cornell-Kennon, Susan; Schaefer, Erik M; Katzhendler, Jehoshua; Marcinkiewicz, Cezary; Hoffman, Amnon; Lazarovici, Philip. (2021). Synthesis and Pharmacological Characterization of Visabron, a Backbone Cyclic Peptide Dual Antagonist of α4β1 (VLA-4)/α9β1 Integrin for Therapy of Multiple Sclerosis.. JACS Au, 1(12), 2361-2376. https://doi.org/10.1021/jacsau.1c00496
MLA
Gilon, Chaim, et al. "Synthesis and Pharmacological Characterization of Visabron, a Backbone Cyclic Peptide Dual Antagonist of α4β1 (VLA-4)/α9β1 Integrin for Therapy of Multiple Sclerosis.." JACS Au, 2021. https://doi.org/10.1021/jacsau.1c00496
RethinkPeptides
RethinkPeptides Research Database. "Synthesis and Pharmacological Characterization of Visabron, ..." RPEP-05406. Retrieved from https://rethinkpeptides.com/research/gilon-2021-synthesis-and-pharmacological-characterization
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.